Abcam, ab313628, Anti-TRIP12/ULF antibody [EPR27062-86]

Size: 20µL / 100µL / 1mL
Anti-TRIP12/ULF antibody [EPR27062-86] is a Rabbit Monoclonal antibody that is used in TRIP12/ULF Flow Cytometry (Intra), ICC/IF, IHC-P, Western Blot. Suitable for Human, Mouse, Rat samples. Thyroid hormone receptor interactor 12 (TRIP12) is an E3 ligase most notably involved in the proteolytic degradation of the tumor suppressors p14ARF and p19ARF. TRIP12 responds to DNA damage and oncogenic stress by targeting RNF168 and p19ARF for proteolysis. TRIP12 inactivation causes FBW7 protein accumulation and increased proteasomal degradation of the SCFFBW7 substrate Myeloid Leukemia 1 (MCL1), and sensitizes cancer cells to anti-tubulin chemotherapy. Conversely, TRIP12 is associated with distant metastasis-free survival in breast cancer, suggesting an inhibitory role in metastasis.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27062-86,
Isotype:IgG,
Carrier free:No,
Reacts with:Human, Mouse, Rat,
Applications:ICC/IF, IHC-P, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TRIP12 also known as Thyroid Hormone Receptor Interactor 12 or ULF (Ubiquitin Ligase for FBW7) is an E3 ubiquitin ligase. Mechanically TRIP12 facilitates the ubiquitination and subsequent proteasomal degradation of specific proteins. It has an approximate mass of 220 kDa. This protein is expressed in various tissues including the brain and liver. TRIP12 often interacts with other proteins through its ARM and HECT domains playing an important role in regulating protein stability.
Biological function summary
TRIP12 functions as a regulator of protein turnover impacting processes such as cell cycle progression and DNA damage responses. It is not part of a larger complex but operates independently to exert its influence. The target specifically targets proteins like p53 and FBW7 for degradation allowing cells to maintain homeostasis and adapt to changing conditions. This regulation ensures cells respond appropriately to DNA damage by either promoting repair pathways or facilitating apoptosis when repair is not feasible.
Pathways
TRIP12 plays a role in the ubiquitin-proteasome system and the p53 signaling pathway. In the ubiquitin-proteasome system TRIP12 works alongside other E3 ligases to regulate protein degradation ensuring proteins that are damaged or no longer needed are efficiently removed. Within the p53 signaling pathway TRIP12 influences the stability and activity of the tumor suppressor protein p53 helping control cell cycle arrest and apoptosis. TRIP12's relationship with FBW7 further connects it to pathways involved in cancer as FBW7 targets many oncoproteins.
TRIP12 has links to cancer and neurodevelopmental disorders. Alterations in the activity or expression of TRIP12 can lead to the accumulation of proteins like p53 which may contribute to tumorigenesis. Mutations in TRIP12 have also been associated with neurodevelopmental disorders where disrupted protein turnover impacts neural development. Its interaction with proteins such as p53 and FBW7 highlights its potential role in disease mechanisms making it a target of interest for therapeutic intervention.